Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 104 | SFEIES24 | Next issue

Joint Irish-UK Endocrine Meeting 2024

Belfast, Northern Ireland
14 Oct 2024 - 15 Oct 2024

Card image cap

Oral Poster Presentations

Oral Posters 2 – Diabetes/Obesity/Metabolism 1

ea0104op5 | Oral Posters 2 – Diabetes/Obesity/Metabolism 1 | SFEIES24

The role of soluble epoxide hydrolase in metabolic-associated fatty liver disease

Li Pin-Hsuan , Juan Chi-Chang

Metabolic-associated fatty liver disease (MAFLD) is a metabolic disorder characterized by excessive lipid accumulation and is associated with irreversible liver cirrhosis and liver cancer. Epoxyeicosatrienoic acids (EETs), which are synthesized from fatty acid metabolism, function primarily as a regulator of vascular tone, anti-inflammation, and angiogenesis. Soluble epoxide hydrolase (sEH) is a key enzyme that converts EET to the less biologically active dihydroxyeicosatrieno...

ea0104op6 | Oral Posters 2 – Diabetes/Obesity/Metabolism 1 | SFEIES24

11β-HSD1 inhibitor efficacy in type 2 diabetes is cortisol-dependent

Wilton-Waddell Atinuke , Abi Farraj Layal , Vasconcelos Elton JR. , Byrne Emily , Taylor Angela E. , Freeman Adrian , Etal Damla , Stewart Paul M. , Arlt Wiebke , Ajjan Ramzi , Tiganescu Ana

Cortisol excess drives multiple adverse effects including hypertension, dyslipidemia, and delayed wound healing. Activation of cortisol by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) has shown promise as a therapeutic target for these comorbidities but clinical progress has been hampered by variable 11β-HSD1 inhibitor efficacy. Transcriptomic profiling by RNA-seq found 611 11β-HSD1 target genes in primary skin fibroblasts (n = 3),...

ea0104op7 | Oral Posters 2 – Diabetes/Obesity/Metabolism 1 | SFEIES24

Hybrid acylated and non-acylated GLP-1 and apelin receptor co-agonist peptides, show promising acute in vivo anti-hyperglycaemic actions in normal healthy and insulin resistant diet-induced obese mice

O'Harte Finbarr , Palmer Ethan , Craig Sarah , Irwin Nigel

Incretin mimetics, alongside associated hybrid co-agonist peptides, which activate GLP-1 and other receptors are leading the way to more effective therapeutic options for management of obesity and type 2 diabetes. The adipokine apelin, which activates the APJ receptor, has shown anti-diabetic and obesity related therapeutic utility following pre-clinical testing. The present study investigated several novel hybrid co-agonist peptides, derived from exendin-linker-apelin (ELA) a...